OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Substance Abuse Treatment is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine	97
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19	90
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder	87
Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic	83
A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose	76
Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings	74
A systematic review of stigma interventions for providers who treat patients with substance use disorders	73
Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19	71
Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study	64
Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study	62
Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use	50
Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19	50
Experiences of racial discrimination in the medical setting and associations with medical mistrust and expectations of care among black patients seeking addiction treatment	47
Online digital recovery support services: An overview of the science and their potential to help individuals with substance use disorder during COVID-19 and beyond	46
COVID-19-related treatment service disruptions among people with single- and polysubstance use concerns	46
Family involvement in treatment and recovery for substance use disorders among transition-age youth: Research bedrocks and opportunities	45
Telehealth sustains patient engagement in OUD treatment during COVID-19	43
Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island	43
Difficult binds: A systematic review of facilitators and barriers to treatment among mothers with substance use disorders	42
Impacts of COVID-19 on residential treatment programs for substance use disorder	42
Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19	42
The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19	42
Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms	41
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?	39
Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic	38

Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis	38
Adolescent substance use: Challenges and opportunities related to COVID-19	36
“A good mother”: Impact of motherhood identity on women's substance use and engagement in treatment across the lifespan	35
Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?	35
Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine	34
COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings	33
“You have to take this medication, but then you get punished for taking it:” lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period	33
A scoping review of alcohol, tobacco, and other drug use treatment interventions for sexual and gender minority populations	33
A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, he	32
Experiences of stigma in hospitals with addiction consultation services: A qualitative analysis of patients' and hospital-based providers' perspectives	32
The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review	32
Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities	32
Digital delivery of a contingency management intervention for substance use disorder: A feasibility study with DynamiCare Health	32
Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic	31
Patterns of substance use before and after hospitalization among patients seen by an inpatient addiction consult service: A latent transition analysis	31
Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis	31
Adapting methadone inductions to the fentanyl era	29
“In their mind, they always felt less than”: The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention	29
Mobile methadone medication units: A brief history, scoping review and research opportunity	28
Contingency management for treatment attendance: A meta-analysis	28
Racial/ethnic and gender differences in receipt of brief intervention among patients with unhealthy alcohol use in the U.S. Veterans Health Administration	27
Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects	27
Changes in methadone take-home dosing before and after COVID-19	27
Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic	27
A feasibility study providing substance use treatment in the Black church	26
Engaging the justice system to address the opioid crisis: The Justice Community Opioid Innovation Network (JCOIN)	26
The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives	26
How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic	25
Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder	25
Patient-centered care's relationship with substance use disorder treatment utilization	25
A chance to do it better: Methadone maintenance treatment in the age of Covid-19	25
Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder	24
Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic	24
Drug and alcohol treatment utilization and barriers among Black, American Indian/Alaskan Native, Latine, Asian/Pacific Islander/Native Hawaiian, and White adults: Findings from NESARC-III	24
A smartphone-smartcard platform for contingency management in an inner-city substance use disorder outpatient program	24
Substance use treatment in Appalachian Tennessee amid COVID-19: Challenges and preparing for the future	23
Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)	23
Exploring first responders' perceptions of medication for addiction treatment: Does stigma influence attitudes?	23
Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program	23
Peer recovery services for persons returning from prison: Pilot randomized clinical trial investigation of SUPPORT	22
The Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS): A hybrid type-1 effectiveness trial of enhanced primary care to improve opioid use d	22
Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19	22
A systematic literature review of clinical trials and therapeutic applications of ibogaine	21
A collision of crises: Addressing an HIV outbreak among people who inject drugs in the midst of COVID-19	21
Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series	21
Legalization of cannabis use in Canada: Impacts on the cannabis use profiles of youth seeking services for substance use	21
Healthcare utilization patterns among persons who use drugs during the COVID-19 pandemic	21
The intersection of race and opioid use disorder treatment: A quantitative analysis	21
Integrated substance use and prenatal care delivery in the era of COVID-19	21
“No home to take methadone to”: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston	21

Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada	21
COVID-19 innovations in medication for addiction treatment at a Skid Row syringe exchange	20
Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder	20
Racial/ethnic disparities in the availability of hospital based opioid use disorder treatment	20
Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders	20
Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response	19
With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic	19
Mobile low-threshold buprenorphine integrated with infectious disease services	19
Considering the harms of our habits: The reflexive urine drug screen in opioid use disorder treatment	19
COVID-19 and treating incarcerated populations for opioid use disorder	19
Facilitators and barriers to post-overdose service delivery in Rhode Island emergency departments: A qualitative evaluation	18
Bridge clinic buprenorphine program decreases emergency department visits	18
“I have to be around people that are doing what I'm doing”: The importance of expanding the peer recovery coach role in treatment of opioid use disorder in the face of COVID-19 health disparities	18
Providing addiction services during a pandemic: Lessons learned from COVID-19	18
Kentucky Women's Justice Community Opioid Innovation Network (JCOIN): A type 1 effectiveness-implementation hybrid trial to increase utilization of medications for opioid use disorder among justice-in	18
The role of perceived treatment need in explaining racial/ethnic disparities in the use of substance abuse treatment services	18
Feasibility and acceptability of a digital health intervention to promote engagement in and adherence to medication for opioid use disorder	17
Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada	17
Sharp decline in hospital and emergency department initiated buprenorphine for opioid use disorder during COVID-19 state of emergency in California	17
Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency	17
Research on substance use disorders during the COVID-19 pandemic	17
Telemedicine works for treating substance use disorder: The STAR clinic experience during COVID-19	17
Overdose deaths from nonprescribed prescription opioids, heroin, and other synthetic opioids in Medicare beneficiaries	17
Value of family involvement in substance use disorder treatment: Aligning clinical and financing priorities	17
Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives	17
Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: A qualitative study in Vancouver, Canada	17
Revising our attitudes towards agonist medications and their diversion in a time of pandemic	17
Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting	16
A Facebook intervention to address cigarette smoking and heavy episodic drinking: A pilot randomized controlled trial	16
“They went down that road, and they get it”: A qualitative study of peer support worker roles within perinatal substance use programs	16
Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma	16
Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general prac	16
Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults	16
Substance use among women who are pregnant: Examining treatment completion by race and ethnicity	16
Recovering from substance use disorders during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City	16
Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19	16
It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment	15
Using machine learning to identify predictors of imminent drinking and create tailored messages for at-risk drinkers experiencing homelessness	15
Factors associated with psychotic symptoms among a sample of male prisoners with substance use disorder: A cross-sectional study	15
“If I had them, I would use them every time”: Perspectives on fentanyl test strip use from people who use drugs	15
Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic	15
National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness	15
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse	15
Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year	15
Parent SMART (Substance Misuse in Adolescents in Residential Treatment): Pilot randomized trial of a technology-assisted parenting intervention	15
Healthcare utilization of individuals with substance use disorders following Affordable Care Act implementation in a California healthcare system	15
Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention	15
Characterizing trends in methamphetamine-related health care use when there is no ICD code for “methamphetamine use disorder”	15
“Sick and tired of being sick and tired”: Exploring initiation of medications for opioid use disorder among people experiencing homelessness	15
Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges	14
What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings	14
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services	14
Traditions and Connections for Urban Native Americans (TACUNA): Utilizing community-based input to develop an opioid prevention intervention for urban American Indian/Alaska Native emerging adults	14
Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support	14
Treatment options and shared decision-making in the treatment of opioid use disorder: A scoping review	14
A pilot randomized clinical trial of Brief Behavioral Treatment for Insomnia to reduce problematic cannabis use among trauma-exposed young adults	14
Parental status and characteristics of women in substance use treatment services: Analysis of electronic patient records	14
Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic	14
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail	14
The next wave? Mental health comorbidities and patients with substance use disorders in under-resourced and rural areas	14
Cannabis use disorder and post-traumatic stress disorder: The prevalence of comorbidity in veterans of recent conflicts	14
Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic	14
Caring for women with substance use disorders through pregnancy and postpartum during the COVID-19 pandemic: Lessons learned from psychology trainees in an integrated OBGYN/substance use disorder outp	14
Increased availability of telehealth mental health and substance abuse treatment for peripartum and postpartum women: A unique opportunity to increase telehealth treatment	14
Long-acting depot buprenorphine in people who are homeless: Views and experiences	14
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)	14
Using structured implementation interventions to improve referral to substance use treatment among justice-involved youth: Findings from a multisite cluster randomized trial	13
Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities	13
Is behavioral activation an effective and acceptable treatment for co-occurring depression and substance use disorders? A meta-analysis of randomized controlled trials	13
Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing	13
Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail	13
Improving retention across the OUD service cascade upon reentry from jail using Recovery Management Checkups-Adaptive (RMC-A) experiment	13
Extended-release naltrexone for youth with opioid use disorder	13
The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth	13
Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder	13
A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations	13
Youth OUD treatment during and after COVID: Increasing family involvement across the services continuum	13
Drum-Assisted Recovery Therapy for Native Americans (DARTNA): Results from a feasibility randomized controlled trial	13
Competing risks of women and men who use fentanyl: “The number one thing I worry about would be my safety and number two would be overdose”	13
Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic	13